There is no female version of Viagra, but two FDA-approved medications do exist for women with persistently low sexual desire. They work completely differently from Viagra and target the brain rather than blood flow, which reflects a fundamental difference in how sexual dysfunction typically presents in women versus men.
Why Viagra Itself Doesn’t Work for Women
Viagra (sildenafil) increases blood flow to the genitals, which effectively treats erection problems in men. Researchers did test it in women. Small trials found that sildenafil could reduce the time to orgasm and increase subjective arousal in some groups, including postmenopausal women on estrogen therapy. But the results were inconsistent across broader populations, and the drug never earned FDA approval for women.
The core issue: for most women who report sexual dysfunction, the problem isn’t physical arousal or blood flow. It’s a lack of desire. The body may be capable of responding, but the mental interest or drive isn’t there. That distinction pushed researchers toward brain chemistry instead of blood vessels.
The Two FDA-Approved Options
Addyi (Flibanserin)
Approved in 2015, Addyi is a daily pill for premenopausal women with persistently low sexual desire that causes personal distress. It’s not a hormone. It works by shifting the balance of brain chemicals: boosting dopamine and norepinephrine (both linked to motivation and arousal) while lowering serotonin activity that can suppress desire. Think of it less like a “female Viagra” and more like an ongoing rebalancing of your brain’s interest signals.
You take it every night at bedtime, and it typically takes several weeks of daily use before effects become noticeable. In clinical trials, women taking Addyi reported roughly one additional satisfying sexual experience per month compared to women on a placebo. That’s a modest benefit, and it’s one reason the drug has been polarizing. Some women find it meaningfully improves their quality of life; others feel the effect isn’t worth the commitment or side effects.
The biggest practical limitation is alcohol. You need to wait at least two hours after having one or two drinks before taking your dose. If you’ve had three or more drinks, you skip that night’s dose entirely. After taking Addyi at bedtime, you shouldn’t drink alcohol until the following day. Mixing the two too closely can cause a dangerous drop in blood pressure or fainting. Common side effects include dizziness, sleepiness, and nausea, which is partly why it’s taken at bedtime.
Cost is another barrier. Without insurance, Addyi runs around $1,960 for a 30-day supply, though discount programs exist and some insurance plans cover part of the cost.
Vyleesi (Bremelanotide)
Vyleesi takes a different approach. Rather than a daily pill, it’s a self-injection you give yourself at least 45 minutes before anticipated sexual activity. It activates pathways in the brain involved in sexual response, working on demand rather than building up over time.
There are firm limits on how often you can use it: no more than one dose in 24 hours and no more than eight doses per month. The most common side effect is nausea, which can be significant enough that some women stop using it. Unlike Addyi, Vyleesi doesn’t have the same alcohol restriction, which makes it more practical for some lifestyles.
What These Medications Are Designed to Treat
Both drugs are approved for a specific condition, not general dissatisfaction or occasional low interest. The diagnostic criteria require that reduced sexual desire has persisted for at least six months and causes you significant personal distress. At least three specific patterns need to be present, such as little to no interest in initiating sex, rarely experiencing sexual thoughts or fantasies, reduced pleasure during sexual activity, or not responding to cues that previously sparked interest.
Crucially, the low desire can’t be explained by relationship problems, another mental health condition, medication side effects, or a medical issue. If an antidepressant is killing your sex drive, for instance, the first-line approach is usually adjusting that medication rather than adding another one. If stress or relationship conflict is the root cause, a pill won’t address the underlying problem.
Why the Options Are So Limited
Female sexual desire is shaped by hormones, brain chemistry, psychological state, relationship dynamics, and life circumstances all at once. That complexity makes it genuinely harder to develop a single drug that works broadly. Viagra solved a relatively straightforward plumbing problem. The female equivalent would need to influence motivation, emotional responsiveness, and physical sensation simultaneously, and no single molecule does all of that well.
Some clinicians prescribe testosterone off-label for postmenopausal women with low desire, since testosterone plays a role in libido for all genders. This isn’t FDA-approved for women, and long-term safety data is limited, but it’s a common enough practice that your doctor may bring it up depending on your situation.
What to Realistically Expect
If you’re hoping for something that works like Viagra does for men (take a pill, feel the effect within an hour), neither approved option delivers that experience. Addyi requires weeks of nightly use for a modest increase in desire. Vyleesi is closer to on-demand but still needs to be injected well before the moment and doesn’t work for everyone.
Many women with low desire find that a combination of approaches works better than medication alone. Therapy focused on sexual concerns, addressing hormonal changes (especially around menopause), reducing stress, and working on relationship communication can all move the needle. Medication can be one piece of that picture, but it’s rarely the whole answer.